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Objective: Irritable bowel syndrome (IBS) has been associated with psychiatric comorbidity and alterations
in serotonergic metabolism. Tryptophan is the precursor of serotonin (5-HT), but it is mainly catabolized
through the kynurenine pathway. This pathway may also be involved in the pathogenesis of IBS by virtue
of deviating tryptophan from the 5-HT pathway resulting in 5-HT deﬁciency. We therefore aimed to ascertain
the mucosal and systemic concentrations of 5-HT and kynurenic acid (KYNA), a principal kynurenine
metabolite.
Methods: Duodenal mucosal biopsy specimens and platelet poor plasma samples were obtained from 15
healthy volunteers and 15 IBS patients. Psychological state was assessed using the Hospital Anxiety and
Depression Scale and the Symptom Checklist-90.
Results: IBS patients showed signiﬁcantly lower mucosal and higher systemic concentrations of both 5-HT
and KYNA compared to healthy controls. Also, signiﬁcant correlation between mucosal but not plasma
concentrations of KYNA and 5-HT and psychological state in IBS was observed.
Conclusion: The observation that mucosal KYNA and 5-HT are both decreased in IBS does not support the
hypothesis that increased activation along the kynurenic pathway results in relative 5-HT deﬁciency.
However, an increased release of these substances from the intestine to the systemic compartment may
lead to a decrease in intestinal KYNA and 5-HT levels, resulting in disturbance of intestinal homeostasis.
Thus, changes in psychological states observed in IBS patients may be secondary to alterations in gastrointes-
tinal function, and in particular kynurenine and/or 5-HT metabolism.© 2013 Elsevier Inc. Open access under the Elsevier OA license.Introduction
Irritable bowel syndrome (IBS) is a functional gastrointestinal disor-
der affecting up to 15% of the Western population. Despite being very
common, the pathophysiology of IBS is incompletely understood [1].
Several studies have provided evidence that IBS is associated with a
dysregulation of the brain–gut axis — a theoretical concept describing
a bidirectional connection, of which serotonin (5-hydroxytryptamine,
5-HT) appears to be an important modulator [2]. In the periphery,
5-HT is involved in mediating gastrointestinal secretion, motility and
perception, whereas in the central nervous system (CNS), 5-HT modu-
lates an extensive range of physiological and behavioral processes
[3]. 5-HT is derived from tryptophan. Merely 1% of ingested tryptophanne,Division ofGastroenterology–
x 5800, 6202 AZ Maastricht, the
ity.nl (D. Keszthelyi).
vier OA license.is converted into 5-HT, while the majority is catabolized via the
kynurenine pathway, the primary route of tryptophan metabolism in
the human body [4]. Metabolites of the kynurenine pathway have re-
cently received increasing attention, as they are also believed to have
a regulatory role in both the CNS and the gastrointestinal tract [4,5].
We have recently demonstrated that these two metabolic path-
ways (5-HT and kynurenine) compete for their mutual precursor
tryptophan, in particular following acute stress [6]. This implies that
diversion of tryptophan to the kynurenine pathway may potentially
lead to a relative deﬁciency of 5-HT synthesis and hence serotonergic
dysfunction. This concept of pathway imbalance has been suggested
as a factor involved in the development of disorders associated with
serotonergic dysfunction in both CNS and periphery [4,7]. Such a met-
abolic dysfunction may also provide a mechanistic link between IBS
and its high comorbidity with psychiatric conditions such as affective
and anxiety disorders. The aim of this study was therefore threefold.
First, we aimed to assess the mucosal and systemic concentrations of
kynurenic acid (KYNA), a principal kynurenine metabolite, suggested
to play a role in gastrointestinal function [8], in IBS patients compared
Table 1






Age 44±13 33±17 .06
Gender 46% male 33% male .35
BMI 27±5 24±4 .08
HADS 3 (0–10) 0 (0–4) .001
HADS-D 2 (0–6) 0 (0–4) .007
HADS-A 0 (0–4) 0 (0–0) .03
Global Severity Index (SCL-90) 117 (91–164) 94 (90–106) b .001
IBS=irritable bowel syndrome; BMI=body mass index; HADS=Hospital Anxiety and
Depression Scale; SCL-90=Symptom Checklist-90.
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temic concentrations of 5-HT, in order to ascertain the relationship be-
tween the two pathways. Third, we aimed to ascertain the association
between potential alterations in 5-HT and KYNA concentrations with
psychological state.
Methods
This studywas part of a larger project investigating the role of 5-HT
in IBS approved by the Medical Ethics Committee of the Maastricht
University Medical Centre (MUMC) and was conducted according to
the revised version of the Declaration of Helsinki (October 2008,
Seoul). All participants gave their written informed consent prior to
participation. The study has been registered at the US National Library
of Medicine (http://www.clinicaltrials.gov, NCT00731003).
Participants
Fifteen healthy volunteers and 15 patients with IBS diagnosed
according to the Rome III criteria were included. Exclusion criteria
included history of gastrointestinal disorders other than IBS; use of
psychoactive medication (including serotonin reuptake inhibitors);
and use of medication inﬂuencing gastrointestinal function within
14 days prior to testing. During the screening period, psychological
state was assessed using the 17-item Hospital Anxiety and Depres-
sion Scale (HADS) and the Symptom Checklist-90 (SCL-90). Global
Severity Index on the SCL-90 was used to assess general psychological
state.
Study procedures
Participants arrived at the MUMC after an overnight fast at
8:00 AM. Blood samples were drawn from the antecubital vein. Here-
after, at 10:00 AM, participants underwent a gastroduodenoscopy,
during which mucosal samples from the horizontal part of the duode-
num were obtained and immediately frozen in liquid nitrogen. The
rationale for taking duodenal samples was that this part of the intes-
tine has a high turnover of 5-HT and recent reports suggest an impair-
ment of serotonergic function in the duodenum in IBS [9].
Assessment of kynurenic acid and 5-HT concentrations
Blood samples were collected using pre-chilled K2EDTA tubes. To
avoid oxidative breakdown, 1 ml 1.4% ascorbic acid (Sigma Aldrich,
St. Louis, MO) was added to the tubes. Platelet poor plasma samples
were obtained by centrifuging tubes at 2000 g at 4 °C for 10 min.
Supernatants were allocated and immediately frozen at−80 °C until
analysis. Biopsy specimens were weighed and homogenized prior
to analysis. Concentrations of 5-HT and KYNA were determined by
HPLC–MS as described previously [6].
Statistical analyses
The descriptive statistical analyses were performed using SPSS
20.0 for windows (SPSS Inc., Chicago IL). Data were tested for normal-
ity by the Kolmogorov–Smirnov test. Normally distributed data were
analyzed by Student's t-test. Mann–Whitney U-test was used for
non-parametric data. Coefﬁcients for correlations were calculated
according to Pearson and Spearmen, respectively. Data are expressed
as mean±SEM, if not otherwise indicated. A Bonferroni correction was
applied for multiple testing of correlations with psychiatric scores.
Results
Table 1 describes demographic characteristics and psychological score. Distribu-
tion of IBS subtypes was as follows: 46% diarrhea predominant, 33% constipation pre-
dominant, 20% mixed subtype.Plasma and mucosal KYNA concentrations
Plasma concentration of KYNA was signiﬁcantly higher in IBS compared to healthy
controls (2.96±0.33 vs 0.36±0.019 nmol/l, pb .0001, see Fig. 1A). On the contrary,
mucosal concentrations of KYNA were signiﬁcantly lower in IBS patients compared
to healthy controls (0.30±0.10 vs 1.36±0.52 pmol/mg wet tissue, p=.02, see
Fig. 1B). A signiﬁcant negative correlation was found between mucosal and plasma
concentrations of KYNA (r=−0.45, p=.03), suggesting an inverse relationship
between these two pools of KYNA. No association was found between age, gender or
IBS subtype and KYNA concentrations.
Plasma and mucosal concentrations of 5-HT
A similar pattern of alterations was found in IBS with regard to 5-HT concentra-
tions. Plasma concentration of 5-HT was signiﬁcantly higher in IBS compared to
healthy controls (26.2±4.7 vs 1.9±0.35 nmol/l, pb .0001, see Fig. 1C). In contrast, mu-
cosal concentrations of 5-HT were signiﬁcantly lower in IBS patients compared to
healthy controls (12.6±3.4 vs 51.9±17.6 pmol/mg wet tissue, p=.008, see Fig. 1D).
On the contrary, a signiﬁcant negative correlation was found between mucosal and
plasma concentrations of 5-HT (r=−0.42, pb .05). No association was found between
age, gender or IBS subtype and 5-HT concentrations.
Correlation between 5-HT and KYNA concentrations
We also investigated whether there was any relation between levels of 5-HT and
KYNA. We found a signiﬁcant negative correlation between plasma 5-HT and KYNA
concentrations both in healthy controls (r=−0.60, p=.03) and in IBS patients
(r=−0.62, p=.02), suggesting an inverse relation. On the other hand, no correlation
was found between mucosal concentrations of 5-HT and KYNA in either group (data
not shown).
Correlations with psychological score
In IBS patients, a signiﬁcant correlation was found between mucosal 5-HT and
HADS score (r=0.66, p=.02) but not with the SCL-90 score (r=0.15, p=.64). When
subdividing the HADS score into domains of depression and anxiety, mucosal 5-HT
concentrations signiﬁcantly correlated with the HADS-D score (r=0.74, p=.006) but
not with HADS-A score (r=0.25, p=.42). Furthermore, a signiﬁcant negative correla-
tion was found between mucosal KYNA concentration and SCL-90 (r=−0.57, pb .05)
but no correlation was found with the HADS score (r=−0.34, p=.27). In contrast to
mucosal 5-HT and KYNA, no correlations were found for plasma 5-HT and KYNA con-
centrations and HADS or SCL-90 in IBS. It is important to note that following Bonferroni
correction for multiple testing, only correlation between mucosal 5-HT and HADS-D
score remained signiﬁcant.
In healthy controls, no correlation was found between HADS scores and SCL-90
and either plasma or mucosal 5-HT concentrations or plasma or mucosal KYNA con-
centrations (data not shown).
Discussion
A number of studies have found evidence for a dysregulation in
the kynurenine pathway in IBS. The present study, although limited
in sample size, is the ﬁrst to report on both mucosal and systemic
levels of KYNA. We found decreased mucosal levels and increased
systemic levels of KYNA in IBS patients. KYNA is an antagonist at
the N-methyl-D-aspartate and nicotinic cholinoreceptors and an ago-
nist at the orphan G-protein-coupled receptor GPR35, at which KYNA
is one of the most potent endogenous agonists yet identiﬁed [10].
GPR35 has been shown to have anti-nociceptive properties and has
therefore been suggested as an important target to counteract inﬂam-
matory pain [11]. The highest levels of GPR35 are in the intestine, and
Fig. 1. Plasma and mucosal concentrations of kynurenic acid and serotonin (5-HT) in patients with irritable bowel syndrome (IBS) and healthy controls. *pb .05; ***pb .001.
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KYNA [12]. In the intestine, KYNA is known to have neuroprotective,
anti-oxidative and anti-inﬂammatory properties and is believed to
play a role in gut motility and sensory functions [13]. Decreased
mucosal concentrations of KYNAmay therefore potentially contribute
to functional, neural, metabolic or inﬂammatory derangements that
facilitate the development of gastrointestinal disorders, such as IBS.
Interestingly, we found increased plasma levels of KYNA in IBS,
although it is important to note that ﬁndings in literature are not
consistent [14–16]. Earlier studies showing increased plasma levels
of kynurenic acid in patients with inﬂammatory bowel disease
suggested that this increase may represent either a compensatory
response to elevated activation of enteric neurons or a primary ab-
normality which induces a compensatory increase in gut activity
[17]. Systemic levels of kynurenine metabolites are largely under con-
trol of the liver by clearing any excess tryptophan through tryptophan
dioxygenase (TDO), the initiating enzyme of the kynurenine pathway.
Another source of kynurenine metabolites in plasma is derived from
the activity of extrahepatic indoleamine-2,3-dioxygenase, largely
expressed by the intestine [4]. KYNA is synthesized from kynurenine
by action of kynurenine aminotransferase, expressed primarily in the
liver, intestine and kidney [18]. The source of increased plasma KYNA
concentrations is therefore most probably peripheral, as KYNA only
poorly penetrates the blood–brain barrier [19]. Increased systemic
concentrations of KYNA may reﬂect either 1) increased activity of
hepatic TDO or 2) increased release of KYNA from extrahepatic
sources, such as the intestine. The former seems less likely since
previous reports have suggested decreased TDO activity in IBS [15].
The latter, however, is supported by the inverse relationship between
intestinal mucosal and systemic levels of KYNA observed in our study.
An increased release of KYNA from the mucosa into to systemic com-
partment could therefore result in mucosal KYNA deﬁciency, poten-
tially contributing to intestinal dysfunction.
We also assessed 5-HT concentrations to ascertain their relation to
KYNA concentrations. Levels of 5-HT in both plasma and mucosa
showed a pattern similar to KYNA levels in IBS: signiﬁcantly elevatedplasma concentrations and decreased mucosal concentrations com-
pared to healthy controls. Previous studies in IBS have also demon-
strated higher plasma 5-HT levels [20] and lower 5-HT levels in
mucosa of IBS patients [21], although it is noteworthy that consider-
able discrepancies still exist in data from various reports [22].
Plasma concentrations of 5-HT and KYNA were found to be in-
versely related in our study. However, the observation that plasma
KYNA and 5-HT are both increased in IBS does not support the hypoth-
esis that increased activation along the kynurenic pathway results in
relative 5-HT deﬁciency contributing to disease development. Fur-
thermore, no correlation was found in mucosal concentrations of
5-HT and KYNA. It is important to note, that wemeasured only a single
metabolite of the kynurenine pathway, which is not necessarily repre-
sentative of the entire spectrum of kynurenine metabolites. Thus, it
cannot be excluded that both alterations in 5-HT and kynurenine
metabolism play a role in IBS, regardless of whether these changes
are interdependent. A more complete proﬁling of mucosal and sys-
temic concentrations of these metabolites should therefore add to
our understanding of the role of the kynurenine pathway in IBS.
We also ascertained whether these changes in 5-HT and KYNA
concentrations were associated with psychological state. We found
no correlation between plasma concentration of 5-HT or KYNA and
HADS or SCL-90 in IBS, which is in line with the ﬁndings of Park et
al. [23]. However, more interestingly, we observed a signiﬁcant corre-
lation between mucosal concentrations of 5-HT and psychological
state in IBS patients. Apart from the disturbances in the 5-HT pathway,
kynurenic pathway dysregulation has previously been associatedwith
affective disorders [24]. Plasma levels of kynurenic acid have either
been shown to be decreased [25] or unchanged in this patient group
[26]. Patients with depression (without gastrointestinal comorbidity)
generally also have lowered plasma levels of 5-HT [24,27]. Considering
the increased plasma levels of 5-HT and KYNA in IBS and the lack of
correlation with psychological scores, we postulate that the changes
in psychological state observed in IBS patients in our study may be
secondary to alterations in gastrointestinal function, and in particular
kynurenine and/or 5-HT metabolism. This is an important assumption
504 D. Keszthelyi et al. / Journal of Psychosomatic Research 74 (2013) 501–504since IBS patients have been shown to be hypervigilant regarding
gastrointestinal symptoms [28]. Potential alterations in gastrointestinal
homeostasis may therefore be augmented by hypervigilance and con-
tribute to increased disease burden. Consistent with this hypothesis
is that cognitive behavioral therapy only indirectly improves bowel
symptoms through improvement of mood and anxiety [29].
Due to the preliminary nature of our ﬁndings and the relatively small
sample size, further research is warranted to conﬁrm the formulated hy-
potheses. It is also important to note that no differentiation was made
with regard to different IBS subtypes. Furthermore, correlations with
psychological scale should be interpreted with caution, as the small
sample size and stringent multiple hypothesis corrections are factors
possibly causing false negatives results. Findings of this study will there-
fore need to be substantiated in a larger group of patients.
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